Clearside Biomedical, Inc. Announces Proposed Offering of Common Stock
07 December 2016
Clearside Biomedical , Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock. All of the shares in the offering will be sold by Clearside. In addition, Clearside expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of common stock at the public offering price, less the underwriting discount.
U.S. patent agency to weigh rival claims on gene-editing technology
07 December 2016
The U.S. patent agency on Tuesday will hear arguments in a heated dispute over who was first to invent a revolutionary gene-editing technology known as CRISPR.
07 December 2016
Global medicine spending will reach nearly $1.5 trillion by 2021 on an invoice price basis, up nearly $370 billion from the 2016 estimated spending level. Importantly for the outlook is that spending growth is slowing in 2016, declining from nearly 9% growth in 2014 and 2015 to just 4–7% CAGR over the next five years.
Is the US biopharma industry headed for a turning point in 2017?
07 December 2016
Three months ago, Brent Saunders fired a shot across the bow of the USS Big Pharma, pledging to limit Allergan’s annual price increase on its portfolio drugs to no more than single-digit percentage hikes each year. On Monday, the new US president of diabetes specialist Novo Nordisk took that pledge. And 2017 is shaping up as a potential turning point in the heated public argument over drug prices in the US.
Small flu vax players poised to win 'sizable' share of market, firm predicts
06 December 2016
As new flu vaccine technology emerges in the coming years, smaller players will have a shot at stealing market share from the world leaders who have for years had a hold on the market.
EU health regulator warns some hep C drugs could reactivate hep B
05 December 2016
The European Medicines Agency warned on Friday that some of the most successful hepatitis C treatments on the market could reactivate hepatitis B in patients, the second time this year it has raised safety concerns over these treatments.
Influenza vaccine ‘desperately’ needs improvement
05 December 2016
The current seasonal influenza vaccine is not perfect, but experts agree that it remains the best available tool for fighting influenza — at least for now.
Pharma executives weigh in on possible changes under Trump
02 December 2016
Top executives from large U.S. drugmakers on Thursday discussed for the first time possible changes for the industry under President-elect Donald Trump, and issues that have damaged the reputation of their industry.
Biotech’s biggest protesters are turning into its supporters
02 December 2016
For decades the biotech industry has been hounded by activists over animal testing. Most notably, a campaign against Huntington Life Sciences in the late 1990s through 2000s included arson, harassment, threats and alleged fire bombings. Less severe, but still troubling for biotech, animal rights activists join with anti-GMOers most years to protest at the Biotechnology Innovation Organization (BIO) convention.
Immunization Administration and the Future of Pharmacy
01 December 2016
CDC officials report that more than 25% of influenza vaccines are administered by pharmacists. It would be safe to say that the immunization role of pharmacists has become an important public health success. The American Pharmacists Association (APhA) has more than 300,000 pharmacists trained as immunizers.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
New breast cancer guidelines call for first mammogram at age 40 but stop short of annual screening
08 May 2024
WHO proposes recommendations for preventing nitrosamine contamination
07 May 2024
Batyr Berdyklychev is now head of the WHO office in Russia
07 May 2024
Russia expects more medical tourism due to the world’s first drug for ankylosing spondylitis
07 May 2024